Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Wouter Jukema

Showing results (671-680 of 928) with videos related to

Pageof 93
Sort By:
European Heart Journal|August 31, 2010
A single dose of erythropoietin in ST-elevation myocardial infarctionAdriaan A Voors, Anne M S Belonje, Felix Zijlstra, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 27, 2014
Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesityMariëtte R Boon, Sander Kooijman, Andrea D van Dam, et al.
Circulation|July 24, 2012
Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohortsBaris Gencer, Tinh-Hai Collet, Vanessa Virgini, et al.
BMJ Open|March 24, 2018
Prevalence of potentially inappropriate prescribing in a subpopulation of older European clinical trial participants: a cross-sectional studyDavid O Riordan, Carole Elodie Aubert, Kieran A Walsh, et al.
American Journal of Epidemiology|January 11, 2022
Evaluation of the Value of Waist Circumference and Metabolomics in the Estimation of Visceral Adipose TissueSebastiaan C Boone, Maarten van Smeden, Frits R Rosendaal, et al.
European Heart Journal|May 24, 2019
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trialHarvey D White, Ph Gabriel Steg, Michael Szarek, et al.
Circulation|November 9, 2005
Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)Chris J Packard, Ian Ford, Michele Robertson, et al.
Frontiers in Immunology|May 29, 2024
CCL18 aggravates atherosclerosis by inducing CCR6-dependent T-cell influx and polarizationAnjana Singh, Adriaan O Kraaijeveld, Adelina Curaj, et al.
Circulation|September 3, 2019
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary SyndromesMatthew T Roe, Qian H Li, Deepak L Bhatt, et al.
Circulation|December 28, 2018
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular RiskMichelle L O'Donoghue, Sergio Fazio, Robert P Giugliano, et al.
Pageof 93

Showing results (671-680 of 928) with videos related to

Sort By:
Pageof 93
European Heart Journal|August 31, 2010
A single dose of erythropoietin in ST-elevation myocardial infarctionAdriaan A Voors, Anne M S Belonje, Felix Zijlstra, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 27, 2014
Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesityMariëtte R Boon, Sander Kooijman, Andrea D van Dam, et al.
Circulation|July 24, 2012
Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohortsBaris Gencer, Tinh-Hai Collet, Vanessa Virgini, et al.
BMJ Open|March 24, 2018
Prevalence of potentially inappropriate prescribing in a subpopulation of older European clinical trial participants: a cross-sectional studyDavid O Riordan, Carole Elodie Aubert, Kieran A Walsh, et al.
American Journal of Epidemiology|January 11, 2022
Evaluation of the Value of Waist Circumference and Metabolomics in the Estimation of Visceral Adipose TissueSebastiaan C Boone, Maarten van Smeden, Frits R Rosendaal, et al.
European Heart Journal|May 24, 2019
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trialHarvey D White, Ph Gabriel Steg, Michael Szarek, et al.
Circulation|November 9, 2005
Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)Chris J Packard, Ian Ford, Michele Robertson, et al.
Frontiers in Immunology|May 29, 2024
CCL18 aggravates atherosclerosis by inducing CCR6-dependent T-cell influx and polarizationAnjana Singh, Adriaan O Kraaijeveld, Adelina Curaj, et al.
Circulation|September 3, 2019
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary SyndromesMatthew T Roe, Qian H Li, Deepak L Bhatt, et al.
Circulation|December 28, 2018
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular RiskMichelle L O'Donoghue, Sergio Fazio, Robert P Giugliano, et al.
Pageof 93